Computed tomography (CT) has become an important modality in the evaluation of coronary artery disease (CAD). The tremendous technological advances in CT in the last two decades has made it possible to obtain high quality images of coronary arteries with high spatial and temporal resolutions. Multiple trials have confirmed the accuracy of CT compared to invasive catheter angiography. CT is also able to evaluate beyond the lumen in characterizing and quantifying atherosclerotic plaques, including evaluation of high risk features. Although CTA has low specificity in identification of lesion-specific ischemia, functional techniques are now possible such as CT myocardial perfusion and CT-fractional flow reserve (FFR) which evaluate the hemodynamic significance of stenosis and help with revascularization strategies. Multi-energy CT provides additional information beyond what is possible with a conventional CT and is useful in variety of clinical applications, including myocardial perfusion imaging, lesion characterization and low contrast studies. Large trials have confirmed the ability of CT to predict major adverse cardiovascular events and recent trials have even demonstrated improved clinical outcomes by using CT for the evaluation of CAD. CT is also useful in structural heart disease and 3 D printing is now increasingly used for surgical/interventional planning. Machine learning is evolving rapidly and is likely to impact diagnosis and management.
Introduction
Coronary artery disease (CAD) remains the leading cause of mortality worldwide, often fatal at the time of first presentation. Cardiac Computed Tomography (CT) has become an integral imaging modality in the evaluation of CAD, facilitated by dramatic technological advances in the last decade, which has resulted in consistent acquisition of high quality images of the coronary arterial lumen as well as the wall with high accuracy and relatively low radiation doses. Large trials have also established the predictive capabilities of CT for future major adverse cardiovascular events (MACE) as well as improved outcomes by using CT. In this article, we provide an overview of this fast evolving world of coronary CT imaging.
Technology
Although obtaining good quality images of the coronary arteries was a challenge in the early days of cardiac CT, they are now consistently obtained by reducing motion using ECG-gating, slowing heart rate with beta blockers and dilating coronary arteries with nitroglycerine. Faster gantry rotation times and dual source scanners have also improved temporal resolution (up to 66 milliseconds), which effectively freezes the cardiac motion in the images, enabling good quality images even at higher heart rates and arrhythmias. Motion artifacts can also be minimized by adjusting placement of the reconstruction window, ECG-editing and motion compensation/edge correction algorithms. Improvements in detector technology, detector electronics and deflection of focal spot have improved the spatial resolution (up to 0.23 mm in-plane). A prototype scanner with 0.25 mm detectors potentially allows a 140 l spatial resolution. Spatial resolution is also improved with advanced filters and model-based iterative reconstruction algorithms. Single heartbeat scanning is now possible, either with a wide-detector array/volume scanner (up to 16 cm coverage in one rotation) or a high-pitch helical mode in a dual source scanner and these allow for motion-free images as well as the use of low contrast volumes. 1 Cardiac scanning is now possible at low energy, i.e.
70 kVp in patients with lower BMI, which improves the contrast attenuation and allows the use of low volumes of contrast media.
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A prototype stereo CT dedicated to cardiac imaging is being developed with two side-by-side x-ray sources, a single detector, focused field of view and ultra-short geometry that has faster rotation, lower cone-beam artifacts and lower radiation dose.
Radiation dose
Technological advances have also helped in minimizing radiation doses, which had been a concern in the initial days of cardiac CT. This has been made possible by using prospective ECG triggering, in which data is acquired in only a specific phase of the cardiac cycle instead of retrospective ECG-gating where data is acquired throughout the R-R interval. Even if retrospective-ECG gating is opted due to high heart rate/arrhythmia, ECG-based tube current modulation can be used to minimize radiation doses. Adaptive low tube current and tube voltage based on body size also helps in minimize radiation dose. Anatomybased tube current modulation varies the radiation dose based on the body size and anatomy. Iterative reconstruction algorithms facilitate the use of low radiation dose protocols by minimizing noise that is seen in such studies. All these strategies have made it possible to perform high-quality cardiac CT with less than 1 millisievert of radiation dose.
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Multi-energetic CT
Conventional CT in which a polyenergetic x-ray beam with a single peak energy is utilized is limited in discriminating tissues with similar attenuation CT numbers (HU). Multi-energetic CT (Spectral CT/Dual-energy) obtains data at multiple energies (typically 2) and can achieve improved characterization of tissues since different tissue behave differently at different energy levels. There are several technologies of multi-energetic CT, some of which are source based (Dual source, rapid tube voltage switching, dual-spin, split-beam) and some are detector based (Dual layer, photon counting). In addition to conventional CT images, additional spectral images including virtual monoenergetic, iodine-map, virtual non-contrast and effective atomic number-based are obtained using these technologies (Figure 1 ). In addition, a novel CT fingerprinting image type can also be obtained by plotting of the Compton and photoelectric components. Each tissue occupies a specific space in this map, which can be used for more accurate material characterization and elemental analysis independent of energy. All these images are used in several exciting applications in cardiovascular imaging including-(1) Myocardial perfusion imaging-To enhance lesion detection and decrease artifacts; (2) Improve vascular contrastto salvage suboptimal vascular studies and use low volumes of contrast; (3) decrease artifacts-beam hardening, calcium blooming and metallic streaks; (4) lesion characterization-plaques, thrombus, masses, incidental extracardiac lesions; (5) Quantification-iodine, iron; (6) Minimizing radiation dose-with virtual non contrast instead of true non contrast and saving additional imaging tests for lesion characterization; (7) Improved sensitivity to novel contrast agents such as gold nanoparticles. 4 
Accuracy
The accuracy of CT in the detection of coronary stenosis has been well established beyond doubt and is concordant with invasive coronary angiography (ICA). Earlier studies showed high sensitivity (86-100%) and NPV (93-100%) for detection of significant stenosis compared to ICA, but with lower specificity and positive predictive values (50-90%), 5 especially in densely calcified plaques which result in overestimation of luminal stenosis due to calcium blooming. Multiple early trials including the ACCURACY and CORE-64 studies, found that on a per-patient basis, the average sensitivity and NPV were 93%, with specificity of 79% and PPV of 80%. [6] [7] [8] [9] A metaanalysis showed a pooled sensitivity, specificity, PPV and NPV on per patient bases for 64/40 slice scanners of 96%, 91%, 93% and 96%, respectively, 10 and another showed values of 99%, 89%, 93% and 100%, respectively. 11 A recent study showed that CTA is more accurate compared to ICA than other non-invasive functional testing including stress/rest myocardial perfusion imaging (SPECT/PET) and wall motion (stress echo/ MRI), on a per-patient basis with sensitivity of 91% (73, 45% for MPI and wall motion respectively), specificity of 92% (67, 90%), PPV of 83% (53, 62%), NPV of 96% (83, 82%) and AUC of 0.91 (0.74, 0.70).
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The high negative predictive value of CT makes it ideal for excluding coronary stenosis in the low to intermediate risk population.
Beyond the lumen
CT provides comprehensive information beyond the coronary arterial lumen, including the arterial wall, heart and extra cardiac structures. CT allows detection, characterization and quantification of atherosclerotic plaques, which is not possible with ICA or other functional tests. CT can evaluate several features including plaque burden (thickness, area, volume), content (calcified, spotty, non-calcified, mixed), biomechanical information (plaque force, axial surface stress) and additional information (diffuseness, density, systemic inflammation, effect of therapy). High risk plaque features (vulnerable plaque) include -positive remodeling, low attenuation from lipid-rich core, thin fibrous cap, spotty calcification and napkin ring sign ( Figure 2 ). 13 These features, particularly positive remodeling and low attenuation plaque are seen in acute coronary syndrome (ACS) and may regress after statin therapy. CT can evaluate other cardiac features including morphology, function, valves and the pericardium. CTA is used in structural heart disease for the planning of procedures including TAVR, TMVR, LAA devices and others. 3d printing based on CT data helps planning for complex surgeries/interventions by providing anatomical information as well as procedural simulation, which increases the operator confidence and decreases the procedure time. It is also useful in therapeutic imaging, where custom-made patient specific endovascular devices can be designed. 3d printing also helps in medical as well as patient education.
Hemodynamic significance of stenosis
A major limitation of CT is its low specificity and accuracy in detecting lesion-specific ischemia (48% and 64%), 14 often being the least amongst other current imaging modalities. 15 Functional test is essential to improve patient outcomes by identifying relevant ischemia-inducing lesions, decreasing unnecessary ICA, determining prognosis, guiding management and planning appropriate revascularization strategy. This is now possible with CT myocardial perfusion imaging (MPI), CT-FFR and transluminal attenuation gradient (TAG). CT MPI is performed after intravenous contrast administration, both at rest and after pharmacological stress with adenosine/regadenoson, either in a static or a dynamic mode, either with single or multi-energetic mode.
In ischemia, qualitative analysis shows perfusion defect in the stress images, either in grayscale display or in color maps ( Figure 3 ). With dynamic myocardial perfusion, semiquantitative and quantitative evaluation can be performed. A time attenuation curve can be plotted based on the enhancement of myocardium over time and in ischemia, the peak enhancement, rate of rise of myocardial enhancement and area under the curve are diminished. By using model-based deconvolution analysis, absolute myocardial blood volume can be quantified without a need for a normal reference, with a cut-off of 75 ml/100 ml/min distinguishing ischemia. 16 MPI shows improved specificity (68-98%) and PPV (55-94%) in the diagnosis of ischemia 17 compared to conventional CTA. However, MPI is associated with additional radiation and contrast. CT-FFR is a novel technique which does not require additional scanning, medication or radiation. From a routine coronary CTA dataset, computational fluid dynamic (CFD) model of coronary blood flow is generated by a supercomputer, either offsite or onsite. Using assumptions for resting myocardial blood flow, microvascular resistance and hyperemic state and by solving the Navier Stokes equation, flow and pressure across the coronary artery can be calculated and FFR obtained. A cut-off of 0.8 is considered to be abnormal with high accuracy on comparison with invasive FFR 18 ( Figure 4 ). CT-FFR has an overall specificity of 70% (including DISCOVER-FLOW, DEFACTO NXT trials), compared to 35% for conventional CTA, as a result of which 68% of CT false positives were converted to true negatives. 18 This obviates the need for ICA in 61% of patients who would have got it based on conventional CTA alone. 19 However, there is no change in PCI rates (32% in usual vs. 29% in CT-FFR), 19 and the short term outcome for those who had deferred ICA was good, making CT a more effective gatekeeper for ICA.
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There was also lower cost by $3000 and 12% fewer events at 1-year compared to ICA and visual guidance. 21 In many centers,
CT-FFR data is requested if there is a moderate luminal stenosis, to evaluate if the lesion is hemodynamically significant; however, it should be noted that CT-FFR is abnormal in 16.6% of patients with < 50% stenosis (ischemia without stenosis), is normal in 33% of patients with > 70% stenosis (stenosis without ischemia) and is abnormal only in 50% of those with moderate stenosis. In serial stenosis, CT-FFR can help in identifying the lesion that specifically causes ischemia and needs revascularization. 20 CT-FFR can be used to predict the outcome of PCI by placing a virtual stent across lesion and evaluate the change in flow. CT-FFR requires high image quality and does not work in rest angina.
Transluminal attenuation gradient (TAG) along the coronary arteries from a routine coronary CTA has also been used to estimate the hemodynamic significance of stenosis, particularly with a single heartbeat scanner. 22, 23 TAG is calculated from the change in HU per 10 mm length of coronary artery and is the linear regression coefficient between intra-HU and length from ostium (in mm). The TAG is significantly lower in FFRsignificant vessels, with a cut off of -15.1 HU/10 mm predicting FFR < 0.8 with good accuracy. 22 The accuracy of TAG is not affected by calcification and the AUC for detection improved when combining TAG and CTA.
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Emergency room
Cardiac CT is an effective tool in the triage of ER patients presenting with acute chest pain. Of the 8-10 million presenting to an ER in the USA with chest pain, 85-95%% have a final diagnosis other than ACS, with many unnecessary admissions and high medical costs. CTA can reliably exclude CAD in low to intermediate risk ER patients and large trials (64-STAT, CT-STAT, ACRIN PA 4005 and ROMICAT II) have shown reduction in time to diagnosis (by 54%), higher rate of CAD diagnosis (9.0 vs. 3.5% in non-CT pathway), shorter length-of-stay in ER (22 vs. 31 h), fewer negative ICAs, higher rates of safe discharge (50% vs. 23%), cost savings (38%) and low 30-day MACE after a negative CTA (0-0.75%), making it a safe and effective test with good warranty period of at least 2 years. 24 There is also no significant difference in resource utilization at 30 days and 1 year. 24 CT is also useful for evaluating cardiac function, wall motion abnormalities, perfusion defects and non-cardiac causes of chest pain. However, long -term studies are needed to evaluate over-utilization and downstream costs. CT may not be appropriate in the high-risk population due to low specificity with high calcium and those with coronary stents.
Predictive value
CT provides ample information on prediction of future cardiovascular events and prognosis, which is essential for early initiation of preventive treatment at a subclinical stage. Patients with high (> 300) coronary arterial calcium score (CAC) have up to 10-fold higher risk of events than those without 25 and have been shown to benefit from statins 26 ( Figure 5 ). The presence of any CAC (> 0), even after accounting for other risk factors indicates a higher risk of having future CHD or CVD in next decade. 27 CAC is useful across wide spectrum of age and risk factors, 28 but particularly improves risk prediction in the intermediate risk group when combined with other traditional clinical risk stratification models, due to its ability to reclassify and helps in determining those who need aggressive statin therapy. 29 Low-risk group with high CAC (> 100) is associated with 10 year event rate of 10%, whereas high-risk group with CAC of 0, have a 10 year event rate of 3%. Practically, CAC is most useful in patients in the intermediate group, i.e. ASCVD risk of 5-20% who are considered/recommended stains. If the CAC is low/absent in these individuals (absent in 53% of these), statins may be deferred based on risk/benefit analysis, particularly in those who are averse or intolerant to it, and if the CAC is high, it can be used to convince them to have statins. 30 It is also useful in those with premature family history of CHD, which is not accounted in the traditional risk scores. CAC also helps in risk stratification in diabetes/metabolic syndrome, who are traditionally considered CHD risk equivalent, but 38-45% of these patients have a CAC of 0 with annual CHD event rate similar to those without diabetes/metabolic syndrome, thus reclassifying the risk. 31 High CAC is also associated with heart failure, atrial 34 In the near future, imaging combined with biomarkers and genetics will play an important role in preventive medicine. Non-obstructive disease (plaques) seen in CTA but not in other functional tests confers heightened risk (MACE) over 5-year period both in men and women, with higher risk in diabetics than non-diabetics based on data from CONFIRM Registry. 35, 36 On a patient level, high-risk plaque features (positive remodeling, low attenuation plaque) are incremental and independent risk factors for ACS in the short term 37 as well as medium term (10 years), 38 with 45-fold and 9-fold higher risk respectively than those without these features. The prediction is superior to stenosis > 70% and history of prior ACS. With lesion-based analysis, 50% of ACS occur due to HRP and 50% on non HRP. 38 Plaque progression by CTA is another independent predictor of ACS (38) , with a 33.4-fold risk of ACS, compared to 8-fold for prior ACS history. 38 70% of ruptured plaques have luminal stenosis > 50%, 39 but 30% have luminal stenosis < 50%, indicating that there are other features that predict ACS, possibly FFR < 0.8. As noted above in CT-FFR, there can be stenosis without ischemia and ischemia without stenosis. Emerging evidence indicates that large necrotic core with positive remodeling is associated with lower FFR than non-lipid rich plaques, independent of degree of luminal narrowing, likely due to inability of the already stretched smooth vessels of these positively remodeled vessels to dilate with vasodilators. 40 Biomechanical forces acting on blood vessels derived from CT computational fluid dynamic analysis also provide superior information in predicting ACS than stenosis and HRP features (AUC 0.727 vs. 0.675 vs. 0.673, respectively) and also provides an incremental risk stratification tool. 41, 42 These biomechanical forces include plaque stress from outside (axial/radial plaque stress, wall shear stress), plaque strain (internal composition), radius gradient (DFFRCT, upstream/downstream dominant) and fluid-structure interactions, all of which play roles in plaque initiation and progression. 43 
Clinical efficacy
Conclusive evidence is now available to show that short and long term outcomes are improved by using CTA, primarily due to early and accurate diagnosis leading to initiation of appropriate therapy. Identifying calcified coronary plaques on CT increases the likelihood of initiating medications, lifestyle modifications, 31 reduction in BP & lipids and smoking cessation when compared to those who were managed with standard care without CT. 44 In a study of 1637 patients with > 50% stenosis followed for 3 years, addition of statins was shown to improve the outcome (MACE), with 43% reduction in death. 45 In 10 418 non-obstructive plaques followed for 2.5 years, aspirins and stains improved outcomes with 61% reduction in death, whereas in those without any plaque, no change was seen irrespective of clinical risk. 46 The SCOT-HEART trial examined 4, 146 patients with stable chest pain and showed that with coronary CTA, there is higher certainty and frequency of diagnosis of CAD, higher certainty but lower frequency of diagnosis of angina, more appropriate use of ICA (lower incidence of non-obstructive disease), more initiation and alteration of preventive therapies at 48-52 days after clinic with associated halving of MI and improved patient satisfaction compared to routine pathway without CTA before the patient comes to the visit at 6 weeks. Although overall event rates were similar, MACE was decreased in CT group up to 20 months 47 and there is a 38% reduction in fatal/non-fatal MI at 1.7 years. 48 The PROMISE trial with 10 003 stable chest pain patients showed that with CTA, there is lower event-rate at 1 year (by 33%), lower false-positive ICA (3.4% vs. 4.3%), lower radiation (12.0 vs. 14.1 mSv) and improved triage to surgical revascularization (2x CABG) and improved primary preventive treatment (2 x statins). However, outcomes at 25 months were similar with CCTA and functional testing groups (3.3 and 3%), with more patients in CCTA group undergoing ICA (12.2% vs. 8.1%), and similar cost and quality of life. 49 The CAPP trial of 500 patients with 12 month follow up showed that CCTA was associated with improved angina symptoms, fewer investigations and rehospitalizations compared to exercise ECG. 50 Crescent TRIAL of 350 patients of stable angina with calcium imaging and selective CTA vs. exercise treadmill test, showed that with CTA, the final diagnosis was established sooner, fewer patients reported angina symptoms, lower all-event rate (3 vs. 10%) and less downstream testing with 16% lower costs. 51 A metanalysis of all these studies comparing CT and usual-care confirmed significant reduction in MI, higher incidence of coronary revascularization and no effect in all-cause mortality. 52 In a study of 4244 symptomatic patients without CAD, Budoff et al showed that at follow up of 80 months, death rate was significantly lower in CTA group compared to control group (4.2% vs. 10.8%), with higher event free survival (95.8% vs. 89.2%), resulting in overall risk reduction of 32%. 53 
Standardization, guidelines, appropriateness criteria
With constant advances in technology and knowledge and heterogeneity in scanners and practices, several imaging and clinical societies have taken efforts to standardize the performance, acquisition, interpretation and reporting of coronary CTA, with the publication of appropriateness criteria as well as specific guidelines. [54] [55] [56] Appropriateness criteria are now getting incorporated in clinical decision support models that are integrated in electronic medical records facilitating the physicians to order the appropriate tests. A standardized Coronary Artery Disease Reporting and Data System (CAD-RADS) has been developed to facilitate effective and standardized communication of coronary CTA findings to referring physicians, with specific guidelines on further management. Scores range from 0 to 5, both for stable and acute chest pain, with 0 being complete absence of stenosis and 5 indicating at least one totally occluded coronary artery ( Figure 6 ) ( Table 1) . Modifiers are added for nondiagnostic study (N), stent (S), coronary bypass graft (G) and vulnerable plaque (V) ( Table 1) . 57 This system will also help with education, peer review, quality assurance and research.
Machine learning
Automation is progressively increasing in coronary CTA, allowing processing of large volumes of data and quantitative analysis. Automated methods are currently used for centerline extraction, segmentation, quantification of stenosis, calcium scoring, plaque quantification, cardiac function, myocardial perfusion and FFR. 58 Automated plaque quantification has been shown to improve the prediction of lesion-specific ischemia by FFR over stenosis alone in intermediate stenosis. 59 Automated interpretation and reading has been tried in the ER setting with high sensitivity and NPV compared to ICA and expert reader. 58 The automatic software operates as an initial reader to triage patients with low to intermediate probability, enabling patients without significant stenosis, and using an expert reader only if there is a significant lesion. This also provides confidence to junior level trainees to exclude negative cases and can also act as a second reader for advanced practitioners, although some cases of failure of segmentation have been reported. 58 Although in most current models, humans perform the final quality check, advanced machine learning techniques (artificial intelligence) are now available, which have the capacity of deep learning (e.g. convolutional neural network, multiple layer perception) to automatically incorporate large volumes of new data, constantly update and optimize the algorithm for the next use, without the need for a human quality check. 60 Machine learning using 25 clinical and 44 CTA variables has shown higher AUC for predicting 5-year all-cause mortality than existing clinical or CTA metrics in a study > 10 000 patients undergoing coronary CTA. 60 Machine learning combined with other plaque features has also been shown to be superior in determination of ischemia compared to traditional models such as plaque volume and plaque characteristics. 61 
Conclusion
Coronary Imaging with cardiac CT is a fast evolving field with tremendous technological and knowledge-based advances in the last decade. The diagnostic accuracy and clinical utility of cardiac CT has been well established and it has become an effective gatekeeper both in stable and acute settings. CT generates abundant predictive and prognostic information and recent studies have shown improvement in outcomes by integrating CT in the decision-making process.
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